{"organizations": [], "uuid": "99c2348cfb7f83b53d2a5eb87b05dd8fd41c8ff9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-abbvie-and-neurocrine-biosciences/brief-abbvie-and-neurocrine-biosciences-announce-pdufa-target-date-of-q3-2018-for-elagolix-in-endometriosis-associated-pain-idUSFWN1RN0MF", "country": "US", "domain_rank": 408, "title": "BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T15:31:00.000+03:00", "replies_count": 0, "uuid": "99c2348cfb7f83b53d2a5eb87b05dd8fd41c8ff9"}, "author": "", "url": "https://www.reuters.com/article/brief-abbvie-and-neurocrine-biosciences/brief-abbvie-and-neurocrine-biosciences-announce-pdufa-target-date-of-q3-2018-for-elagolix-in-endometriosis-associated-pain-idUSFWN1RN0MF", "ord_in_thread": 0, "title": "BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain", "locations": [], "entities": {"persons": [{"name": "abbvie", "sentiment": "none"}], "locations": [], "organizations": [{"name": "neurocrine biosciences announce pdufa", "sentiment": "negative"}, {"name": "neurocrine biosciences", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "elagolix in endometriosis associated pain reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10, 2018 / 12:32 PM / Updated 10 minutes ago BRIEF-Abbvie And Neurocrine Biosciences Announce PDUFA Target Date Of Q3 2018 For Elagolix In Endometriosis Associated Pain Reuters Staff 1 Min Read \nApril 10 (Reuters) - Abbvie And Neurocrine Biosciences Announce Pdufa Target Date Of Q3 2018 For Elagolix In Endometriosis : * ASSOCIATED PAIN \n* FDA REQUIRES EXTENDED TIME FOR REVIEW OF ADDITIONAL INFORMATION IN NEW DRUG APPLICATION \n* BASED ON ABBVIEâ€™S REVIEW OF DATA, COMPANY REMAINS CONFIDENT IN NDA AND CONTINUES TO WORK WITH FDA TO BRING ELAGOLIX TO PATIENTS \n* REGULATORY SUBMISSIONS FOR ELAGOLIX IN UTERINE FIBROIDS REMAIN ON TRACK \n* PRESCRIPTION DRUG USER FEE ACT DATE HAS BEEN EXTENDED THREE MONTHS TO Q3 2018 FOR ELAGOLIX Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-10T15:31:00.000+03:00", "crawled": "2018-04-10T15:48:12.007+03:00", "highlightTitle": ""}